WASHINGTON (EGMN)–Treating symptomatic femoropopliteal artery disease with a paclitaxel-eluting peripheral stent beat both percutaneous transluminal angioplasty and provisional bare-metal stenting in achieving vessel patency rates at 12 months in a prospective, randomized trial.
